Lifeboat Foundation

While NASA is well-known for advancing various technologies for the purposes of space exploration, whether it’s sending spacecraft to another world or for use onboard the International Space Station (ISS), the little-known fact is that these same technologies can be licensed for commercial use to benefit humankind right here on the Earth through NASA’s Spinoff program, which is part of NASA’s Space Technology Mission Directorate and its Technology Transfer program. This includes fields like communication, medical, weather forecasting, and even the very mattresses we sleep on, and are all featured in NASA’s annual Spinoff book, with NASA’s 2024 Spinoff book being the latest in sharing these technologies with the private sector.

“As NASA’s longest continuously running program, we continue to increase the number of technologies we license year-over-year while streamlining the development path from the government to the commercial sector,” Daniel Lockney, Technology Transfer Program Executive at NASA Headquarters, said in a statement. “These commercialization success stories continually prove the benefits of transitioning agency technologies into private hands, where the real impacts are made.”

One example is a medical-grade smartwatch called EmbracePlus developed by Empatica Inc., which uses machine learning algorithms to monitor a person’s vitals, including sleep patterns, heart rate, and oxygen flow. EmbracePlus reached mass production status in 2021 and has been approved by the U.S. Food and Drug Administration (FDA) with the goal of using the smartwatch for astronauts on future spaceflights, including the upcoming Artemis missions, along with medical patients back on Earth.

Steve P. Miller, PhD, has spent much of his career figuring out how to shut off autoimmune responses when he observed dying cells acting as carriers of autoantigens that could modulate the immune system. More than 20 years ago, while a professor at Northwestern University’s Feinberg School of Medicine, Miller discovered that dendritic cells (DCs), a subtype of antigen-presenting cells (APCs), could be changed or turned off to send the right signals to make immunologically tolerant T cells, also known as “tolerogenic.”

Miller’s attention turned toward investigating how best to mimic the apoptotic cells, overriding the expression of dendritic cells. So, Miller partnered with polymer chemist Lonnie D. Shea, PhD, who was at the McCormick School of Engineering, to develop a nanoparticle that interacts effectively with dendritic cells.

In 2013, Miller and Shea helped launch a company spun out of Northwestern University, when Shea was still in Chicago, called Cour Pharmaceutical Development Company, to develop innovative nanobiological therapeutics for acute inflammation, autoimmune, and allergic conditions. After years of experimentation, they developed a formula for nanoparticles of the right size and charge that interact well with the immune system, which is the foundation for their proprietary antigen-specific immune tolerance platform.

Whether or not you can work during a stem cell transplant may depend on the type of job you have. The process of a stem cell transplant, with the high-dose treatments, the transplant, and recovery, can take many months. You will be in and out of the hospital during this time. Even when you are not in the hospital, sometimes you will need to stay near it, rather than staying in your own home.

You will be more tired and your ability to concentrate on work may be affected. You will be visiting the hospital two or three times a week after discharge. You may need to spend a few hours in the hospital for blood or platelet transfusions or replacing minerals in your body.

So, if your job allows, you may want to arrange to work remotely part-time. Many employers are required by law to change your work schedule to meet your needs during cancer treatment. Talk with your employer about ways to adjust your work during treatment. You can learn more about these laws by talking with a social worker.

Nanoclusters (NCs) are crystalline materials that typically exist on the nanometer scale. They are composed of atoms or molecules in combination with metals like cobalt, nickel, iron, and platinum, and have found several interesting applications across diverse fields, including drug delivery, catalysis, and water purification.

A reduction in the size of NCs can unlock additional potential, allowing for processes such as single-atom catalysis. In this context, the coordination of organic molecules with individual transition-metal atoms shows promise for further advancement in this field.

An innovative approach to further reduce the size of NCs involves introducing metal atoms into self-assembled monolayer films on flat surfaces. However, it is crucial to exercise caution in ensuring that the arrangement of metal atoms on these surfaces does not disrupt the ordered nature of these monolayer films.

A large number of applications in the chemical industry rely on the molecules NADH or NADPH as fuel. A team led by Professor Dirk Tischler, head of the Microbial Biotechnology working group at Ruhr University Bochum, used a biocatalyst to study their production in detail.

The researchers proved that, in addition to formate, the biocatalyst formate dehydrogenase can also convert formamides. This means, for one thing, that the enzyme can also cleave the difficult-to-break C–N bond. For another, formamides are a common solvent.

“This opens up completely new possibilities for poorly soluble NADH reactions as well as NADPH-dependent reactions,” says Tischler.

Acoustic tweezers can control target movement through the interaction of momentum between an acoustic wave and an object. Due to their high tissue penetrability and strong acoustic radiation force, such tweezers overcome the limitations of optical and magnetic tweezers, thus making them suitable for in vivo cell manipulation.

A research team led by Prof. Zheng Hairong from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences (CAS) has recently developed a new type of acoustic tweezers —the phased-array holographic acoustic tweezers (PAHAT) system—which is based on a high-density planar array transducer capable of generating tunable three-dimensional bulk acoustic waves. The researchers hope this system can realize a pharmacological version of “telekinesis.” The study was published in Nature Communications on June 6.

The in vivo environment is extremely complex, due to the different characteristics of various tissues, organs, bones, blood vessels, and blood flow. Such a complex environment creates a huge challenge: How can acoustic methods be used to “trap” bacteria so they can produce therapeutic effects on tumors?

The latest in the intersection of large language models and life science: virus sequences, virus proteins, and their function.

Large language models improve annotation of prokaryotic viral proteins.

Ocean viral proteome annotations are expanded by a machine learning approach that is not reliant on sequence homology and can annotate sequences not homologous to those seen in training.

After COVID vaccination, it usually takes weeks for our bodies to develop protective antibody responses. Imagine, however, a vaccine that speeds up the production of antibodies against SARS-CoV-2, the virus that spreads COVID-19.

A research team led by Rong Hai, an associate professor of microbiology and plant pathology at the University of California, Riverside, has developed such a vaccine by using preexisting immunity to a separate virus (the influenza virus) to help kickstart the process of making antibodies against SARS-CoV-2.

“Any delay in the immune response to SARS-CoV-2 means there is some time when people are left poorly protected against the virus,” Hai said. “Our vaccine is designed to get people those protective antibody responses faster, so they are not vulnerable to the coronavirus. This is better protection for everyone. It could be especially valuable for people who still lack immunity to SARS-CoV-2, such as children.”

Engineers at MIT, Penn State University, and Carnegie Mellon University have devised a way to manipulate cells in three dimensions using sound waves. These “acoustic tweezers” could make possible 3D printing of cell structures for tissue engineering and other applications, the researchers say.

Designing tissue implants that can be used to treat human disease requires precisely recreating the natural tissue architecture, but so far it has proven difficult to develop a single method that can achieve that while keeping cells viable and functional.

“The results presented in this paper provide a unique pathway to manipulate biological cells accurately and in three dimensions, without the need for any invasive contact, tagging, or biochemical labeling,” says Subra Suresh, president of Carnegie Mellon and former dean of engineering at MIT. “This approach could lead to new possibilities for research and applications in such areas as regenerative medicine, neuroscience, tissue engineering, biomanufacturing, and cancer metastasis.”